Rappta Therapeutics (private company)
See something wrong or missing? Let us know
Offices:Helsinki
Industry:BiotechHealth services
Business model:B2B
Rappta Therapeutics is a biotech company focused on developing first-in-class anti-cancer drugs activating protein phosphatase 2A (PP2A). PP2A is a critical enzyme regulating protein de-phosphorylation and a key tumor suppressor which to date has been very difficult to target pharmaceutically.
Investors:
we tracked 3 investors
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
values in USD
Investments 10.53M
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
Companies with similar profile to Rappta Therapeutics
| Name | Criteria | |
|---|---|---|
 |
Achilles Therapeutics
50%
|
|
 |
Adrenomed AG
50%
|
|
 |
Aprea Therapeutics
50%
|
|
|
Atai Life Sciences
50%
|
|
|
Biofidelity
50%
|
|
|
BoneSupport
50%
|
|
|
CatalYm
50%
|
|
 |
Cell-Easy
50%
|
|
|
Cinclus Pharma
50%
|
|
|
Eagle Genomics
50%
|
|
Belgium
Netherlands
Austria
Switzerland
Denmark
Estonia
Iceland
Latvia
Lithuania
Norway
Ireland
Italy
Portugal
Spain